QPS Holdings and Hepregen Corporation Announce Commercial Partnership
News May 30, 2013
QPS Holdings, LLC and Hepregen Corporation have announced the execution of an agreement between the companies that provides QPS a license to offer drug metabolism and pharmacokinetic (“DMPK”) services to its clients using Hepregen’s products. The agreement provides for offerings in both North America and Europe. The agreement also creates a marketing and sales partnership between the companies, providing for co-promotion of the HepatoPacTM-associated DMPK services. This arrangement is the first such partnership in the field for both companies.
QPS expects to begin offering metabolite identification, profiling, and clearance studies to North American customers before the end of June, and to European customers in the third calendar quarter of this year using HepatoPacTM products. The North American services will be offered from its well established DMPK department in Newark, Delaware, and its newly established DMPK Hepatic Biosciences division based at the Hamner Institutes in Research Triangle Park, North Carolina, using rat, dog, monkey and human HepatoPacTM products.
“Our ability to offer services utilizing Hepregen’s next-generation product portfolio is another demonstration of the QPS commitment to enhancing its leadership position in the ADME field, providing cutting-edge, liver-based in vitro services to the pharmaceutical and agrochemical industry,” stated Dr. Zamas Lam, QPS Senior Vice President of Preclinical Development.
“QPS brings an extraordinary capability and expertise in bioanalytical technology and hepatic cell biology to our partnership and a strong commitment to a progressive vision in the growing field of hepatic sciences,” stated Dr. Vincent Zurawski, Hepregen’s Chief Executive. “Moreover, QPS is an exceptionally well-managed company, as demonstrated by its outstanding record of growth in the last five years. We are extremely pleased to be engaged with such a strong partner in this paradigm-shifting endeavor,” added Dr. Zurawski.
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
New Drug Class: Potential Therapeutics for Alzheimer’s Disease?News
One step closer to an Alzheimer's treatment? Novel class of drugs more precisely blocks production of toxic forms of beta-amyloid.READ MORE
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018